What is Becton, Dickinson and Company (BDX) DCF Fair Value and Intrinsic Value in 2026?

Becton, Dickinson and Company (BDX) intrinsic value is calculated using conservative multi-stage Discounted Cash Flow (DCF) models, 5-year free cash flow trajectories, Graham Numbers, and owner earnings multiples. LocalAlpha tracks real-time margin of safety against live market prices.

What is Becton, Dickinson and Company's historical Return on Invested Capital (ROIC) and Moat Rating?

Becton, Dickinson and Company operates in the Healthcare sector (Medical Instruments & Supplies) with an economic moat rating of NARROW. LocalAlpha tracks 5-year audited quarterly ROIC, operating margin stability, and balance sheet solvency ratios.

What is Becton, Dickinson and Company's financial health rating and Piotroski F-Score?

Becton, Dickinson and Company's balance sheet quality is evaluated using the 9-point Piotroski F-Score, Altman Z-Score solvency model, debt-to-equity ratio, and quick/current liquidity coverage to guard against financial distress.

How does LocalAlpha monitor Becton, Dickinson and Company (BDX) for quarterly SEC filing thesis breaks?

LocalAlpha audits Becton, Dickinson and Company's 10-K, 10-Q, and 8-K regulatory filings on SEC EDGAR within 15 minutes of release. If reported metrics breach an investor's custom ROIC floor, operating margin boundary, or qualitative risk criteria, an autonomous breach audit is dispatched immediately.

StocksBDX

BDX

Becton, Dickinson and CompanyHealthcare / Medical Instruments & SuppliesINTACT

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Share Price

$177.85

52W: $127.59 - $193.07

DCF Fair Value

$288.71

+38.4% MoS

Thesis Hub

P/E (TTM)

30.7x

ROIC

11.8%

Operating Margin

15.7%

FCF Yield

9.2%

Debt / Equity

0.69x

Piotroski Score

7/9

Altman Z-Score

3.31

Market Cap

$48.4B

Price vs. Intrinsic Value Corridor

Margin of Safety Buy Zone (<25% Discount)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)

—()

Period Range

$— - $—

DCF Fair Value

$288.71

MOS Buy Target (-25%)

$216.53

Valuation Overlays: DCF Fair Value ($288.71) 25% MOS Buy Target ($216.53) Revised Graham ($107.74) Graham Number ($108.06)

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price

$177.85

DCF Fair Value

$289.61

+38.6% MoS

Starting Free Cash Flow ($M)$4,478M

$100M$4,478M (Reported)$50,000M

Stage 1 Growth (Years 1-5)7.9%

-5%10% (Target)35%

Stage 2 Growth (Years 6-10)4.5%

0%5%20%

Discount Rate (WACC / Hurdle)9.0%

6%9% (Standard)15% (High Risk)

Terminal Perpetual Growth2.5%

1% (GDP Floor)2.5% (Inflation)4.0%

Net Debt ($M)$16,100M

-$100B CashBalance Sheet+$150B Debt

10-Yr PV of Cash Flows

$40.5B

PV of Terminal Value

$54.4B

Implied Enterprise Value

$94.9B

Implied Equity Value

$78.8B

Year	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9	Yr 10
Projected FCF ($M)	$4,832	$5,213	$5,625	$6,070	$6,549	$6,844	$7,152	$7,474	$7,810	$8,162
Present Value (PV)	$4,433	$4,388	$4,344	$4,300	$4,257	$4,081	$3,912	$3,751	$3,596	$3,448

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number-64.6% Premium

$108.06

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

EPS: $5.79BVPS: $89.64

Revised Graham Formula-65.1% Premium

$107.74

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Growth Rate (g%)

Bond Yield (Y%)

Buffett Owner Earnings8.8% Yield

$15.64 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $4.3BYield: 8.8%

Reverse DCF: Market Growth Expectation

EXTREMELY LOW BARRIER

-2.6% CAGR (Next 10 Yrs)

At the current price of $177.85, the market is assuming the business will compound Free Cash Flow at -2.6% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict

✓ Low market hurdle: Easy for a wide-moat compounder to beat.

Autonomous Thesis Underwriting

Surveil BDX with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for Becton, Dickinson and Company. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 15.7% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Track BDX & Set Alerts Browse S&P 500 Coverage

Frequently Asked Questions: Becton, Dickinson and Company (BDX) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for Becton, Dickinson and Company.

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, Becton, Dickinson and Company has an estimated DCF intrinsic fair value of $288.71 per share compared to its current market price of $177.85. This represents an estimated 38.4% margin of safety (trading below fair value). Additionally, its classic Benjamin Graham Number stands at $108.06.